TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : RELATED PARTY TRANSACTIONS CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") PROPOSED ACQUISITION OF 806,450 COMMON SHARES IN PANGEN BIOTECH INC. ("PANGEN") ("PANGEN SHARES") REPRESENTING APPROXIMATELY 8.39% EQUITY INTEREST IN PANGEN FROM CHEMICAL COMPANY OF MALAYSIA BERHAD ("CCMB") FOR A TOTAL PURCHASE CONSIDERATION OF RM59.16 MILLION (EQUIVALENT TO KRW16.35 BILLION) TO BE SATISFIED ENTIRELY IN CASH ("PROPOSED ACQUISITION")
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : RELATED PARTY TRANSACTIONS
CCM DUOPHARMA BIOTECH BERHAD (CCMD OR COMPANY) (I) GRANT OF LICENSE FOR TRADE MARKS BY CHEMICAL COMPANY OF MALAYSIA BERHAD (CCMB); (II) PURCHASE OF TRADEMARKS FROM CCMB; AND (III) PROVISION OF INFORMATION TECHNOLOGY (IT) SERVICES BY CCMB.
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : RELATED PARTY TRANSACTIONS
CCM DUOPHARMA BIOTECH BERHAD ("CCMD" OR "THE COMPANY") PROPOSED ACQUISITION OF 806,450 COMMON SHARES IN PANGEN BIOTECH INC. ("PANGEN") ("PANGEN SHARES") REPRESENTING APPROXIMATELY 8.39% EQUITY INTEREST IN PANGEN FROM CHEMICAL COMPANY OF MALAYSIA BERHAD ("CCMB") FOR A TOTAL PURCHASE CONSIDERATION OF RM59.16 MILLION (EQUIVALENT TO KRW16.35 BILLION) TO BE SATISFIED ENTIRELY IN CASH ("PROPOSED ACQUISITION")
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : RELATED PARTY TRANSACTIONS
CCM DUOPHARMA BIOTECH BERHAD (CCMD OR COMPANY) (I) GRANT OF LICENSE FOR TRADE MARKS BY CHEMICAL COMPANY OF MALAYSIA BERHAD (CCMB); (II) PURCHASE OF TRADEMARKS FROM CCMB ; AND (III) PROVISION OF INFORMATION TECHNOLOGY (IT) SERVICES BY CCMB. (COLLECTIVELY, THE TRANSACTIONS)
OTHERS
ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS LETTER OF AWARD) FOR THE SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS PRODUCTS) UNDER MINISTRY OF HEALTHS (MOH) OFF-TAKE AGREEMENT PROGRAM
OTHERS
ACCEPTANCE OF MURABAHAH TAWARRUQ TERM FINANCING FACILITY OF RM250 MILLION (TF-i) AND ISLAMIC MULTI TRADE FACILITIES OF RM30 MILLION (MTF-i) FROM AMBANK ISLAMIC BERHAD (AMBANK OR BANK)
OTHERS
CLARIFICATION WITH RESPECT TO THE ANNOUNCEMENT DATED 25 JANUARY 2017 ON ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS "LETTER OF AWARD") FOR THE SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS "PRODUCTS") UNDER MINISTRY OF HEALTH'S OFF-TAKE AGREEMENT PROGRAM
OTHERS
ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS LETTER OF AWARD) FOR THE SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS PRODUCTS) UNDER MINISTRY OF HEALTHS (MOH) OFF-TAKE AGREEMENT PROGRAM
